抗白血病的

Objective:To evaluate the antileukemic activity and side effects of topotecan-based induction therapy in patients with refractory and relapsed acute myelogenous leukemia(AML). 目的 :評價以拓?fù)涮婵禐榛A(chǔ)的聯(lián)合誘導(dǎo)方案治療難治及復(fù)發(fā)急性粒細(xì)胞白血病 (AML)的療效及不良反應(yīng)。

Minimal residual disease (MRD) as a marker of antileukemic drug efficacy is being used to assess risk status and, in some cases, to adjust the intensity of therapy. MRD作為抗白血病藥物療效標(biāo)志,被用于評估患者危險,在某些病例中也用于調(diào)整治療強度。

METHODS:Leukemic cells from patients with acute leukemia were treated with different antileukemic agents in microwell liquid culture,then the cytotoxicity was measured with MTT assay. 方法：將白血病細(xì)胞與化療藥物微孔液體培養(yǎng)，MTT法檢測細(xì)胞毒性。

METHODS :Leukemic cells from patients with acute leukemia were treated with different antileukemic agents in microwell liquid culture,then the cytotoxicity was measured with MTT assay. 方法： 將白血病細(xì)胞與化療藥物微孔液體培養(yǎng)，MTT法檢測細(xì)胞毒性。

Study of antileukemic effect of CpG-oligodeoxynucleotides treated cord blood 含CpG基序的寡核苷酸介導(dǎo)的臍血抗白血病細(xì)胞作用的研究